Thelansis

  B-Cell Acute Lymphoblastic Leukemia (B-ALL) is a form of blood cancer characterized by the proliferation of abnormal, immature lymphocytes known as blasts within the bone marrow. These blasts are a type of white blood cell called lymphocytes, integral to the immune response. B-ALL exhibits distinctive B-cell-specific antigens such as PAX-5, CD19, CD20, CD22, CD24, and CD79a. While primarily affecting children, especially those under six, it is noteworthy that most cases arise in individuals under 15, with a peak incidence around 40 years of age. Around 20% to 30% of adult ALLs and 5% of pediatric cases involve: The Ph-chromosome Correlating with a poorer prognosis marked by shorter remission durations Reduced survival Heightened resistance to standard chemotherapy Relapsed adult patients commonly experience central nervous system (CNS) involvement. Complete remission rates exceed 95% in children and range from 60% to 85% in adults. However, relapse occurs in 15% t...